Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630001 · ClinicalTrials.gov registry record · Phase 3
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT05630001 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT05630001, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
Interventions
- DRUG Iptacopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630001
The ClinicalTrials.gov registry entry for NCT05630001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iptacopan is the first listed.
NCT05630001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630001 about?
NCT05630001 is a clinical study titled "Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.". The purpose of the study was to find out if iptacopan is effective and safe in adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switched from their current standard of care treatment (eculizumab or ravulizumab) to study treatment, iptacopan/LNP023.
What is the current status of trial NCT05630001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2023-04-24. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT05630001?
The interventions under investigation include: Iptacopan (DRUG).
Who is sponsoring clinical trial NCT05630001?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.